<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01017068</url>
  </required_header>
  <id_info>
    <org_study_id>MRLLSAW</org_study_id>
    <nct_id>NCT01017068</nct_id>
  </id_info>
  <brief_title>Aqueous Mushroom Extract and Intraocular Pressure</brief_title>
  <acronym>AME</acronym>
  <official_title>Aqueous Mushroom Extract as a Glaucoma Agent</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Benin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Benin</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effect of Aqueous mushroom extract (AME) on
      intra ocular pressure (IOP) in humans or as a potential anti glaucoma drug.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Prophet of Islam (Peace Be On Him) was reported to have said that 'mushroom are like
      manna and their water heals eye diseases'(Sahih Bukhari 1985). This statement is being
      investigated in view of the link between blood pressure and intra ocular pressure.

      Glaucoma which is a sight threatening disease and is associated with raised intraocular
      pressure has been treated for a long time with beta blockers. Nowadays the drugs of choice
      are prostaglandin analogs. This study seeks to discover the effect of pleurotus tuberregium
      on raised intraocular pressure and to compare its effect on I.O.P with that of known glaucoma
      drugs. This study also seeks to find out at what concentration pleurotus is effective
      significantly on raised intraocular pressure

      Clinical Investigation will be conducted in the Ophthalmological unit of UBTH in two phases.
      In the first phase 21 relatively young healthy subjects aged less than 50 yrs will be
      recruited for this study after their informed consent. They will have no previous systemic or
      ocular diseases and have an intraocular pressure of 19mmHg or less and a visual acuity of
      6/6. Base line investigations will include the systolic and diastolic blood pressure,
      horizontal pupillary diameter and applanation tonometry. The subjects will be divided into
      three groups of seven each (A1, A2 and A3).

      The study will at first constitute two weeks mushroom treatment, two weeks no mushroom
      treatment and then two weeks mushroom treatment. Treatment will be with aqueous extract of
      Oyster Medicinal mushroom Extract (4g/100ml) dose: п gutt tid x 1/52 for A1, 2g/100ml dose: п
      gutt tid x 1/52 for A2 and 1g/100ml dose: п gutt tid x 1/52 for A3. Investigations of the
      baseline parameters will be done at the start and after each seven days. The subjects will be
      monitored to ensure full compliance with the designed protocol.

      The second phase will involve an equal number of age matched ocular hypertensive or glaucoma
      patient undergoing treatment in UBTH. They will also be divided into three groups of seven
      each and the treatment regimen above repeated. The IOP in this case will be taken by a masked
      observer.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>November 2009</start_date>
  <completion_date type="Anticipated">February 2010</completion_date>
  <primary_completion_date type="Anticipated">February 2010</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>DECREASE INTRA OCULAR PRESSURE</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">42</enrollment>
  <condition>Glaucoma</condition>
  <arm_group>
    <arm_group_label>A1 (glaucoma)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>A2 (glaucoma)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>A3 (glaucoma)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>A1 (normals)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>A2 (normals)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>A3 (normals)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OME</intervention_name>
    <description>4g/100ml) dose: п gutt tid x 1/52</description>
    <arm_group_label>A1 (glaucoma)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OME</intervention_name>
    <description>(2g/100ml) dose: п gutt tid x 1/52</description>
    <arm_group_label>A2 (glaucoma)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OME</intervention_name>
    <description>(1g/100ml) dose: п gutt tid x 1/52</description>
    <arm_group_label>A3 (glaucoma)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OME</intervention_name>
    <description>(4g/100ml) dose: п gutt tid x 1/52</description>
    <arm_group_label>A1 (normals)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OME</intervention_name>
    <description>(2g/100ml) dose: п gutt tid x 1/52</description>
    <arm_group_label>A2 (normals)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OME</intervention_name>
    <description>(1g/100ml) dose: п gutt tid x 1/52</description>
    <arm_group_label>A3 (normals)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  clinical diagnosis of open angle glaucoma

          -  intraocular pressure above 23mmHg

        Exclusion Criteria:

          -  close angle glaucoma

          -  end stage of glaucoma visual field loss

          -  ocular disease other than glaucoma that will interfere with result
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>VINCENT I IYAWE, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Benin, Benin City Nigeria</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>GHALIB A AKINLABI, OD, MSc.</last_name>
    <phone>+2348055200834</phone>
    <email>gaakinlabi@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Eye Clinic University of Benin Teaching Hospital</name>
      <address>
        <city>Benin City</city>
        <state>Edo</state>
        <country>Nigeria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Omolabake T Edema, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Nigeria</country>
  </location_countries>
  <reference>
    <citation>Akinlabi GA, Igbinigie EV, Akpaja EO, Iyawe VI. Preliminary study on the effect of medicinal mushroom extract and timolol maleate on dexamethasone induced ocular hypertension in feline's eye model.Journal of Medicine and Biomedical Research 6(2)63-68. Akinlabi GA, Uzibor HI, Iyawe IO, Iyawe VI. Effect of oyster mushroom exract(pleurotus ostreatus) and latanoprost on intra ocular pressure using cat's eye model. Journal of Medicine and Biomedical Research 8(1)58-64.</citation>
  </reference>
  <verification_date>November 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 19, 2009</study_first_submitted>
  <study_first_submitted_qc>November 19, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 20, 2009</study_first_posted>
  <last_update_submitted>November 23, 2009</last_update_submitted>
  <last_update_submitted_qc>November 23, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 25, 2009</last_update_posted>
  <responsible_party>
    <name_title>Prof. V.I, Iyawe</name_title>
    <organization>Dean, College of Basic Medical Sciences. UNIBEN.</organization>
  </responsible_party>
  <keyword>GLAUCOMA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

